1.Treatment of hyperkalemia (elevated serum potassium) in adults. 2.Not indicated for emergency treatment of life-threatening hyperkalemia due to delayed onset of action.

Potassium-removing Agents

1.Absorption: Not systemically absorbed. 2.Distribution & Metabolism: Not distributed or metabolized systemically (acts locally in GI tract). 3.Excretion: Eliminated unchanged in feces. 4.Onset of action: Serum potassium reduction begins as early as ~1 hour after ingestion, with continued decline as treatment continues.

Known hypersensitivity to sodium zirconium cyclosilicate or any other component of the formulation.

1.Systemic exposure is negligible due to lack of absorption; fetal exposure is not expected. 2.No formal pregnancy category in the PLLR; risk should be assessed clinically.

not expected to result in systemic exposure to infant due to local GI action and negligible absorption.

Most frequently reported adverse reactions include: 1.Edema / fluid retention (dose-related) 2.Hypokalemia (over-correction to low potassium) 3.GI symptoms such as constipation or diarrhea (reported with use)

1.Form: Powder for oral suspension (mix with water). 2.Dosage: (1)Recommended dosing (non-dialysis adults): Initial (correction) phase: 10 g orally three times a day for up to 48 hours. (2)Chronic Hemodialysis Patients (non-dialysis days): 5 g once daily on non-dialysis days; consider 10 g once daily if pre-dialysis potassium > 6.5 mEq/L. 3.Maintenance phase: 10 g once daily; adjust by ±5 g at weekly intervals based on serum potassium; maintenance range 5 g every other day to 15 g once daily. 4.Administration notes: Mix the entire contents of the packet with ?3 tablespoons (?45 mL) of water, stir, and drink immediately. 5.Can be taken with or without food. 6.Because it may transiently increase gastric pH, administer other oral medications with pH-dependent bioavailability at least 2 hours before or after Lokelma, unless clinically directed otherwise.

Safety and effectiveness in pediatric patients not established; not FDA-approved for children.

No specific renal dose adjustments are detailed in the label; dosing recommendations are guided by clinical potassium levels and dialysis status.

No specific hepatic impairment dose adjustments provided; because it is not absorbed systemically, no standard adjustment is recommended.

Store at room temperature; protect from moisture. Powder formulation stable until the expiration date when stored properly (per label).